Drugs / GSK1070806
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT05590338 | Nov 2022 → Jul 2023 | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04975438 | Nov 2021 → Dec 2022 | atopic eczema | GlaxoSmithKline | Completed | Met primary |
| Phase 1 | NCT01035645 | Jan 2010 → Jul 2012 | inflammatory bowel disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03681067 | Feb 2019 → Jun 2020 | Crohn disease | University of Birmingham | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06447506 | Jun 2024 → Jul 2025 | atopic eczema | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05999799 | Nov 2023 → Jul 2025 | atopic eczema | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03522662 | Aug 2018 → Apr 2020 | Behcet disease | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT02723786 | Aug 2016 → Mar 2017 | disease related to solid organ transplantation | GlaxoSmithKline | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01648153 Comparator | Aug 2012 → Sep 2013 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1070806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05590338 ↗ |
| Action | Inhibit | “GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18.” NCT01035645 ↗ |
| Modality | Monoclonal antibody | “GSK1070806 is a humanised monoclonal antibody.” NCT01035645 ↗ |
| Route | Intravenous | “All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline).” NCT01035645 ↗ |
| Target | IL18 | “GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18).” NCT01648153 ↗ |